Non-Viral Gene Delivery Technologies Global Market Report 2025

Description

Non-viral gene delivery technologies are approaches for transferring genetic material into cells without relying on viruses as carriers. These methods reduce safety risks and immune responses associated with viral systems while allowing for precise and controlled delivery. Their primary purpose is to modify or regulate gene expression for the treatment of genetic disorders and the advancement of cell-based therapies.

The main product categories in non-viral gene delivery technologies include reagents and kits, delivery devices, and pre-formulated nanoparticles. Reagents and kits are ready-to-use chemical formulations designed to introduce genetic material into cells without the use of viruses. Delivery can be achieved through various modes, such as in vitro, in vivo, and ex vivo, using technologies like electroporation, lipid-based transfection, polymer-based transfection, physical methods (e.g., microinjection and gene gun), and nanoparticles. These technologies have applications in gene therapy, DNA vaccines, RNA interference (RNAi), CRISPR/Cas9 gene editing, and protein expression. End users include biotechnology and biopharmaceutical companies, research and academic institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The non-viral gene delivery technologies market research report is one of a series of new reports from The Business Research Company that provides non-viral gene delivery technologies market statistics, including non-viral gene delivery technologies industry global market size, regional shares, competitors with a non-viral gene delivery technologies market share, detailed non-viral gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral gene delivery technologies industry. The non-viral gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-viral gene delivery technologies market size has grown rapidly in recent years. It will grow from $3.96 billion in 2024 to $4.57 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth during the historic period can be attributed to the expansion of genetic research, the rising prevalence of chronic genetic disorders, increasing biotechnology and pharmaceutical R\&D activities, advancements in genetic and molecular biology research, and greater government and institutional funding.

The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $8.06 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to the rising demand for personalized medicine, increasing adoption in cancer and rare disease research, the advancement of CRISPR and other gene editing technologies, rapid expansion of mRNA-based therapeutics, and the continued growth of cell therapy and tissue engineering. Key trends expected during this period include advancements in lipid nanoparticles and polymer-based vectors, the development of DNA- and RNA-based therapeutics, integration with artificial intelligence and computational modeling, the emergence of next-generation lipid nanoparticles (LNPs), and continued progress in nanotechnology.

The rising demand for personalized medicine is expected to drive the growth of the non-viral gene delivery technologies market in the coming years. Personalized medicine is a healthcare approach that tailors prevention, diagnosis, and treatment to an individual's unique genetic makeup, lifestyle, and environmental factors. This growing demand is fueled by advances in genomic sequencing technologies, which enable more precise diagnoses, targeted therapies, and improved treatment outcomes customized to each patient. Non-viral gene delivery technologies play a key role in this trend, as they provide safer and more flexible methods for delivering therapeutic genes based on a patient's genetic profile, without the safety risks associated with viral vectors. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases in 2023, compared with 6 approvals in 2022. Therefore, the growing adoption of personalized medicine is fueling the demand for non-viral gene delivery technologies.

Companies in the non-viral gene delivery market are also advancing innovations such as non-viral genetic medicine platforms to improve the safety and precision of gene therapies. These platforms deliver therapeutic genes or nucleic acids into cells without using viruses, lowering the risk of immune responses and other safety concerns while enabling controlled and accurate gene therapy for various diseases. For instance, in October 2023, Generation Bio Co., a US-based biotechnology company, introduced immune-quiet DNA (iqDNA), an enhanced version of its closed-ended DNA (ceDNA). This novel DNA avoids innate immune system detection and demonstrated cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered through its lipid nanoparticle (LNP) system. Due to its improved safety profile, Generation Bio is prioritizing iqDNA as the main DNA cargo across its programs, including its lead hemophilia A treatment.

In September 2023, SOHM Inc., a US-based pharmaceutical company specializing in generic and private-label drugs, acquired ABBIE Inc. for an undisclosed sum. This acquisition strengthens SOHM's position in non-viral gene delivery technologies, enhancing its capacity to develop next-generation gene-editing solutions and expand its footprint in the genetic therapeutics market. ABBIE Inc. is a US-based gene-editing platform company that develops non-viral vector-based delivery systems for genetic payloads.

Major players in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Boehringer Ingelheim GmbH, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corp., Takara Bio Inc., GenScript Biotech Corporation, Poseida Therapeutics Inc., ElevateBio LLC, ProBio Inc., ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

North America was the largest region in the non-viral gene delivery technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-viral gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-viral gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral gene delivery technologies market consists of revenues earned by entities by providing services such as genetic material formulation, delivery system development, and transfection optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-viral gene delivery technologies market also includes sales of lipid nanoparticles, polymer-based carriers, electroporation devices, and microinjection systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Gene Delivery Technologies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-viral gene delivery technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral gene delivery technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral gene delivery technologies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Reagents And Kits; Delivery Devices; Pre-Formulated Nanoparticles
2) By Delivery: In-Vitro; In-Vivo; Ex-Vivo
3) By Technology: Electroporation; Lipid-Based Transfection; Polymer-Based Transfection; Physical Methods (Microinjection, Gene Gun); Nanoparticles
4) By Application: Gene Therapy; Deoxyribonucleic Acid (DNA) Vaccines; Ribonucleic Acid Interference (RNAi); Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing; Protein Expression
5) By End-Use: Biotechnology And Biopharmaceutical Companies; Research And Academic Institutes; Other End-Uses
Subsegments:
1) By Reagents And Kits: Transfection Reagents; Plasmid Deoxyribonucleic Acid (DNA) Kits; Messenger Ribonucleic Acid (RNA) Delivery Kits; Small Interfering Ribonucleic Acid (RNA) Delivery Kits; Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents; Cell-Specific Delivery Reagents
2) By Delivery Devices: Electroporation Systems; Microinjection Systems; Gene Guns Or Biolistic Delivery Devices; Ultrasound-Mediated Delivery Devices; Hydrodynamic Gene Delivery Systems
3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles; Polymer-Based Nanoparticles; Gold-Based Nanoparticles; Dendrimer-Based Nanoparticles; Carbon Nanotube-Based Nanoparticles; Inorganic Compound-Based Nanoparticles
Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; Evonik Industries AG; Moderna Inc.; Boehringer Ingelheim GmbH; Agilent Technologies Inc.; Lonza Group AG; Sartorius AG; Bio-Rad Laboratories Inc.; Bio-Techne Corp.; Takara Bio Inc.; GenScript Biotech Corporation; Poseida Therapeutics Inc.; ElevateBio LLC; ProBio Inc.; ReCode Therapeutics Inc.; Altogen Biosystems Inc.; Generation Bio; Indee Labs Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37838

1. Executive Summary

2. Non-Viral Gene Delivery Technologies Market Characteristics

3. Non-Viral Gene Delivery Technologies Market Trends And Strategies

4. Non-Viral Gene Delivery Technologies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Non-Viral Gene Delivery Technologies Growth Analysis And Strategic Analysis Framework

5.1. Global Non-Viral Gene Delivery Technologies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non-Viral Gene Delivery Technologies Market Growth Rate Analysis
5.4. Global Non-Viral Gene Delivery Technologies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non-Viral Gene Delivery Technologies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non-Viral Gene Delivery Technologies Total Addressable Market (TAM)

6. Non-Viral Gene Delivery Technologies Market Segmentation

6.1. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Reagents And Kits
Delivery Devices
Pre-Formulated Nanoparticles
6.2. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
In-Vitro
In-Vivo
Ex-Vivo
6.3. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Electroporation
Lipid-Based Transfection
Polymer-Based Transfection
Physical Methods (Microinjection, Gene Gun)
Nanoparticles
6.4. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gene Therapy
Deoxyribonucleic Acid (DNA) Vaccines
Ribonucleic Acid Interference (RNAi)
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing
Protein Expression
6.5. Global Non-Viral Gene Delivery Technologies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biotechnology And Biopharmaceutical Companies
Research And Academic Institutes
Other End-Uses
6.6. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Reagents And Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Transfection Reagents
Plasmid Deoxyribonucleic Acid (DNA) Kits
Messenger Ribonucleic Acid (RNA) Delivery Kits
Small Interfering Ribonucleic Acid (RNA) Delivery Kits
Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents
Cell-Specific Delivery Reagents
6.7. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Delivery Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Electroporation Systems
Microinjection Systems
Gene Guns Or Biolistic Delivery Devices
Ultrasound-Mediated Delivery Devices
Hydrodynamic Gene Delivery Systems
6.8. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Pre-Formulated Nanoparticles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lipid-Based Nanoparticles
Polymer-Based Nanoparticles
Gold-Based Nanoparticles
Dendrimer-Based Nanoparticles
Carbon Nanotube-Based Nanoparticles
Inorganic Compound-Based Nanoparticles

7. Non-Viral Gene Delivery Technologies Market Regional And Country Analysis

7.1. Global Non-Viral Gene Delivery Technologies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non-Viral Gene Delivery Technologies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Viral Gene Delivery Technologies Market

8.1. Asia-Pacific Non-Viral Gene Delivery Technologies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Viral Gene Delivery Technologies Market

9.1. China Non-Viral Gene Delivery Technologies Market Overview
9.2. China Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Viral Gene Delivery Technologies Market

10.1. India Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Viral Gene Delivery Technologies Market

11.1. Japan Non-Viral Gene Delivery Technologies Market Overview
11.2. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Viral Gene Delivery Technologies Market

12.1. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Viral Gene Delivery Technologies Market

13.1. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Viral Gene Delivery Technologies Market

14.1. South Korea Non-Viral Gene Delivery Technologies Market Overview
14.2. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Viral Gene Delivery Technologies Market

15.1. Western Europe Non-Viral Gene Delivery Technologies Market Overview
15.2. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Viral Gene Delivery Technologies Market

16.1. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Viral Gene Delivery Technologies Market

17.1. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Viral Gene Delivery Technologies Market

18.1. France Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Viral Gene Delivery Technologies Market

19.1. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Viral Gene Delivery Technologies Market

20.1. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Viral Gene Delivery Technologies Market

21.1. Eastern Europe Non-Viral Gene Delivery Technologies Market Overview
21.2. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Viral Gene Delivery Technologies Market

22.1. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Viral Gene Delivery Technologies Market

23.1. North America Non-Viral Gene Delivery Technologies Market Overview
23.2. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Viral Gene Delivery Technologies Market

24.1. USA Non-Viral Gene Delivery Technologies Market Overview
24.2. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Viral Gene Delivery Technologies Market

25.1. Canada Non-Viral Gene Delivery Technologies Market Overview
25.2. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Viral Gene Delivery Technologies Market

26.1. South America Non-Viral Gene Delivery Technologies Market Overview
26.2. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Viral Gene Delivery Technologies Market

27.1. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Viral Gene Delivery Technologies Market

28.1. Middle East Non-Viral Gene Delivery Technologies Market Overview
28.2. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Viral Gene Delivery Technologies Market

29.1. Africa Non-Viral Gene Delivery Technologies Market Overview
29.2. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Viral Gene Delivery Technologies Market Competitive Landscape And Company Profiles

30.1. Non-Viral Gene Delivery Technologies Market Competitive Landscape
30.2. Non-Viral Gene Delivery Technologies Market Company Profiles
- 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Non-Viral Gene Delivery Technologies Market Other Major And Innovative Companies

31.1. Boehringer Ingelheim GmbH
31.2. Agilent Technologies Inc.
31.3. Lonza Group AG
31.4. Sartorius AG
31.5. Bio-Rad Laboratories Inc.
31.6. Bio-Techne Corp.
31.7. Takara Bio Inc.
31.8. GenScript Biotech Corporation
31.9. Poseida Therapeutics Inc.
31.10. ElevateBio LLC
31.11. ProBio Inc.
31.12. ReCode Therapeutics Inc.
31.13. Altogen Biosystems Inc.
31.14. Generation Bio
31.15. Indee Labs Inc.

32. Global Non-Viral Gene Delivery Technologies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Viral Gene Delivery Technologies Market

34. Recent Developments In The Non-Viral Gene Delivery Technologies Market

35. Non-Viral Gene Delivery Technologies Market High Potential Countries, Segments and Strategies

35.1 Non-Viral Gene Delivery Technologies Market In 2029 - Countries Offering Most New Opportunities
35.2 Non-Viral Gene Delivery Technologies Market In 2029 - Segments Offering Most New Opportunities
35.3 Non-Viral Gene Delivery Technologies Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer